Work Here?
Overview
GenScript Biotech Corporation is a global CRO and biologics CDMO. It provides services and products for life sciences, including custom gene synthesis, peptide synthesis, protein expression/purification, antibody development, and CRISPR, and it supports cell and gene therapy through its ProBio CDMO, Bestzyme enzymes, and Legend Biotech platforms. The company differentiates itself by operating across four platforms that cover research services, end-to-end therapy development, industrial enzymes, and integrated cell therapy, with a global customer base and notable collaborations such as Legend Biotech’s CAR-T program with Janssen. Its goal is to help customers accelerate drug discovery and biopharmaceutical development, scale manufacturing, and bring cell- and gene-therapy products to market.
About GenScript
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Piscataway Township, New Jersey
Founded
2002
Get referred to GenScript
See people who can refer or advise you
Simplify's Take
What believers are saying
- FY2025 revenue hit $959.5 million, up 61.4%, with adjusted net profit reaching $230.3 million.
- TurboCHO launched May 12, 2026, promising antibodies in five days and better yields.
- GenScript’s March and August 2026 partnerships expand demand for rapid wet-lab validation and mRNA workflows.
What critics are saying
- HKEX warned March 10, 2026 of up to $437.9 million Legend impairment and $352.4 million losses.
- Legend deconsolidation left GenScript dependent on a volatile associate, exposing earnings to CARVYKTI swings.
- AI-validation partnerships face commoditization by rivals like Absci, while customer switching costs stay low.
What makes GenScript unique
- GenScript links design-to-validation with Tamarind Bio, shrinking AI discovery handoffs on August 5, 2026.
- The March 12, 2026 Delft mRNA hub gives GenScript European manufacturing, proximity, and regulatory alignment.
- GenScript’s wet-lab scale and Legend heritage differentiate it across gene synthesis, antibodies, and cell therapy.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$500M
Above
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Short Term Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Company Holidays
Paid Sick Days
Compassionate Leave
Jury Duty Leave
Float day
Personal days
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 3%2 year growth
↓ -1%GenScript and Tamarind Bio partner to connect AI Molecular Design with rapid lab validation. Aug 05, 2026, 12:15 ET Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof PISCATAWAY, N.J. and SAN FRANCISCO, Aug. 5, 2026 /PRNewswire/ - Artificial intelligence can now generate thousands of potential drug molecules in the time it once took to design one, dramatically expanding what scientists can imagine. Yet deciding which designs merit further investment still depends on experimental proof. To help address that gap, GenScript Biotech Corporation and Tamarind Bio today announced a strategic partnership connecting Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab validation capabilities. Together, the companies are creating a connected validation engine for AI-enabled discovery, giving scientists a more direct path from AI-generated designs to lab-generated evidence. Through this collaboration, researchers using Tamarind Bio's platform can submit AI-generated sequences and access GenScript's end-to-end wet-lab services, including synthesis, expression, and testing. By reducing manual handoffs between design and validation, the workflow enables teams to generate biological data faster and prioritize promising candidates more efficiently. Addressing a Critical Discovery Bottleneck As AI increases the volume and diversity of molecular designs entering research pipelines, lab capacity and validation have become critical constraints. GenScript's wet-lab infrastructure helps researchers move from digital sequences to model-ready experimental data in as little as four days. With over two decades of biologics expertise, GenScript has built one of the industry's most advanced validation engines for AI-enabled discovery, helping teams evaluate more candidates and build richer datasets to support downstream discovery decisions. "AI is opening doors the industry could only imagine a few years ago," said Ray Chen, President of GenScript Life Science Group. "But biology still determines what moves forward. By connecting AI-powered design to experimental proof, this partnership is helping lay the groundwork for the next generation of scientific innovation." Expanding Access to Molecular Design Tamarind Bio's no-code platform empowers biologics and small molecule researchers with access to more than 300 computational biology models. The platform enables researchers to rapidly test and evaluate AI applications in drug discovery, then scale and execute them for full computational design campaigns. The integration with GenScript extends that capability into the lab, enabling researchers to seamlessly validate promising molecular designs through a single connected workflow. "Tamarind was built to make advanced molecular design accessible to every scientist," said Deniz Kavi, CEO and Co-Founder of Tamarind Bio. "Partnering with GenScript bridges the gap between digital design and physical experimentation, empowering scientists to turn promising candidates into actionable lab results faster than ever." Connecting Design to Decision The partnership reflects a broader shift across the discovery ecosystem: as AI expands what researchers can generate, fast and reliable experimental validation is becoming more important. By connecting AI-powered design with wet-lab validation earlier in discovery, GenScript and Tamarind Bio are enabling researchers to make faster, better-informed decisions about which programs to advance. Earlier validation of promising molecular designs could help accelerate progress across applications ranging from therapeutics and cell and gene therapy to industrial biotechnology. About GenScript Biotech Corporation Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners - from academic institutions to industry leaders - to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com. About Tamarind Bio Tamarind Bio, founded in 2023 in San Francisco, is a unified interface to 300+ molecular AI/ML tools for drug discovery. Tamarind provides scientists with a no-code web interface, AI agent or API to access leading molecular design workflows, including protein structure prediction, de novo design, and simulation. Tamarind is deployed in the majority of the top 20 pharma, and is used by tens of thousands of scientists across industry and academia. For more information, visit www.tamarind.bio.
New Vernon Equities invests $20M in East Hanover Arena campus redevelopment. June 8, 2026 Advertisements. EAST HANOVER - A major office and technology campus redevelopment is taking shape in East Hanover as New Vernon Equities advances work on Arena, a 600,000-square-foot workplace destination near Novartis' northeast headquarters. JLL announced that New Vernon Equities has invested more than $20 million over the past year to reposition two vacant office towers at 20 and 40 Arena Way. The buildings total 350,000 square feet and are part of the larger Arena campus redevelopment. JLL is serving as the exclusive marketing and leasing agent for the properties. Since acquiring the buildings from Novartis, New Vernon Equities has separated the properties from the pharmaceutical company's downsized campus. Improvements include new roadways, independent site access, standalone utility infrastructure, upgraded landscaping, outdoor meeting areas and hospitality-style gathering spaces. The buildings also feature new HVAC systems and a modern building management system. The property holds LEED Gold certification and has been converted to all-electric operations. Interior renovations and next-generation common area amenities are now being finalized, with plans expected to be submitted in the second quarter of 2026 and work scheduled for completion this summer. The full Arena campus spans more than 40 acres and will include six buildings totaling 600,000 square feet of office, research and development, technology and light manufacturing space. New Vernon Equities also acquired nearby properties, including 30 Farinella Drive, a 75,000-square-foot building leased to GenScript for GMP pharmaceutical manufacturing; 31 Farinella Drive, an approximately 50,000-square-foot tech/flex building available for lease; and 80 Arena Way, a 120,000-square-foot tech/flex building expected to begin construction in summer 2026. "It is rare in today's office market to see a developer invest this aggressively on a speculative basis," said Tim Greiner, JLL executive managing director. "New Vernon Equities is delivering infrastructure, sustainability and amenity upgrades that position Arena to compete at the highest level for life sciences, pharmaceutical and innovation-driven users." Arena is located near Route 10 and Ridgedale Avenue, with access to Route 10, Route 24, I-287 and Morristown Airport.
GenScript Biotech has launched the TurboCHO Protein Expression Kit, designed to accelerate antibody production for drug discovery and biologics development. The kit enables labs to generate research-grade proteins in as little as five business days, compared to 10 days for competing solutions. Available in two configurations, the kit delivers up to three-fold higher yields after Protein A purification versus market alternatives, whilst using lower reagent input. The Prime version offers enhanced performance with results as early as Day 3. The product debuted at the PEGS Summit in Boston and is available immediately through GenScript's sales channels. Founded in 2002, GenScript supports over 200,000 customers across 100-plus countries, including the world's top 20 pharmaceutical companies.
GenScript Biotech Corporation and Mimulus Corp have announced a strategic collaboration to industrialise DNA-based data storage, targeting breakthrough cost efficiencies by 2030. The partnership aims to address limitations of existing archival storage systems as AI-driven data creation accelerates. GenScript will scale high-throughput DNA synthesis from millions to billions of oligonucleotides synthesised in parallel on a single chip. The company currently produces 8 million oligonucleotides per chip and brings capabilities across synthesis, sequencing technologies and platform development. Combined with Mimulus' Molecular Archive Technology, the collaboration seeks to create commercially viable molecular storage infrastructure requiring no electricity once data is encoded into DNA. The technology can store massive data volumes for centuries in a credit-card-sized device, potentially freeing power resources for AI supercomputers.
Twist Bioscience Corp stock: pioneering DNA synthesis for biotech innovation and investor opportunities. 02.04.2026 - 03:21:18 | ad-hoc-news.de Twist Bioscience Corp (ISIN: US90130A1016) leads in synthetic DNA manufacturing, enabling breakthroughs in therapeutics, agriculture, and data storage. North American investors eye its scalable platform amid growing demand for custom DNA tools. Explore business model, market position, and key watchpoints. Twist Bioscience Corp stands at the forefront of synthetic biology, offering high-throughput DNA synthesis that powers drug discovery, next-generation sequencing, and industrial biotech applications. Listed on Nasdaq under ticker TWST, its shares trade in USD, with ISIN US90130A1016 representing common stock. Investors focus on its proprietary platform's ability to disrupt traditional phosphoramidite-based synthesis methods. As of: 02.04.2026 By Elena Harper, Senior Biotech Analyst at NorthStar Market Insights: Twist Bioscience Corp exemplifies how silicon chip manufacturing principles revolutionize biological tool production in the synthetic biology sector. Core business model and technology platform. Official source All current information on Twist Bioscience Corp directly from the company's official website. Twist Bioscience Corp develops and manufactures synthetic DNA using a semiconductor-inspired process. The company prints DNA on silicon chips, achieving densities up to 10,000 times higher than conventional methods. This platform supports gene synthesis, next-generation sequencing (NGS) library prep, and antibody optimization. Key products include Twist Gene Fragments for research, Twist Expression Vectors for protein production, and Twist NGS Target Enrichment for clinical diagnostics. The scalable manufacturing reduces costs and turnaround times, addressing bottlenecks in biotech workflows. Revenue streams diversify across biopharma, academic labs, and agrotech firms. Founded in 2013, Twist went public in 2018. Its South San Francisco headquarters anchors operations, with expansion into global markets. The model emphasizes high-volume, low-cost production to capture share in a market projected to grow significantly. Market position and competitive landscape. Sentiment and reactions Twist competes with IDT (Integrated DNA Technologies), GenScript, and Eurofins Genomics in DNA synthesis. Its chip-based approach provides superior throughput and error rates below 1 in 100,000 bases. Partnerships with Illumina and Tempus bolster NGS market penetration. In biopharma, Twist's antibody libraries screen millions of variants rapidly. Agriculture clients use its tools for crop gene editing. Data storage applications explore DNA as an archival medium, with prototypes demonstrating petabyte-scale potential. Market share grows as demand for synthetic biology tools surges. North American biotech hubs like Boston and San Francisco drive adoption. Twist's IP portfolio, including process patents, fortifies barriers to entry. Sector drivers and growth catalysts. Synthetic biology benefits from advances in CRISPR, mRNA therapeutics, and personalized medicine. Regulatory approvals for gene therapies accelerate demand for custom DNA. Global health initiatives post-pandemic emphasize rapid response platforms. Twist's platform aligns with these trends, enabling faster iteration in drug development pipelines. Expansion into NGS consumables taps a recurring revenue model. Industrial biotech for sustainable materials represents a long-term opportunity. North American investors note sector tailwinds from NIH funding and VC inflows into biotech. Supply chain resilience favors U.S.-based manufacturers like Twist. Capacity expansions signal confidence in sustained demand. Relevance for north American investors. For U.S. and Canadian investors, Twist Bioscience Corp offers exposure to synthetic biology without picking individual winners in volatile end-markets. Its Nasdaq listing ensures liquidity and transparency via SEC filings. Dividend-free, growth-oriented profile suits long-term portfolios. Proximity to biotech clusters facilitates collaborations. Tax advantages for U.S. holders apply to capital gains. ESG factors highlight sustainable manufacturing versus chemical-intensive rivals. Portfolio diversification benefits from biotech weighting. Twist complements holdings in sequencing (e.g., Illumina) or CRISPR (e.g., Editas). Watch quarterly revenue breakdowns for biopharma versus NGS balance. Further developments, updates, and context on the stock can be explored quickly through the linked overview pages. Risks and open questions. Competition intensifies as rivals scale. Technology risks include yield variability at high volumes. Dependence on biopharma cycles exposes revenue to R&D budget fluctuations. Regulatory hurdles in gene editing applications loom. Supply chain issues for reagents persist. Intellectual property challenges could arise from broad biotech patents. Open questions center on profitability timelines and market share gains. Investors monitor gross margins and cash burn rates. Geopolitical tensions may impact global expansion. What to watch next. Key catalysts include new partnership announcements and capacity utilization updates. Quarterly earnings will reveal end-market traction. Product launches in data storage merit attention. North American investors should track Nasdaq performance, sector ETFs, and peer comparisons. SEC filings provide deepest insights. Balanced exposure mitigates single-stock risks. Disclaimer: Not investment advice. Stocks are volatile financial instruments. NIS2-Richtlinie 2026: Was Geschäftsführer jetzt über Cyber-Sicherheit wissen müssen. Gratis-Leitfaden: Die neuen EU-Vorgaben zur IT-Sicherheit betreffen mehr Unternehmen als erwartet - bei Verstößen drohen persönliche Haftung und empfindliche Bußgelder. Das kostenlose E-Book "Cyber Security Awareness Trends" erklärt, welche Maßnahmen Pflicht sind und wie Sie Ihr Unternehmen mit minimalem Aufwand compliant machen. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen - dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren. Für. Immer. Kostenlos. US90130A1016 | TWIST BIOSCIENCE CORP | boerse | 69052150 | bgmi
GenScript is Hiring for 55 Jobs on Simplify!
Find jobs on Simplify and start your career today
About GenScript
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Piscataway Township, New Jersey
Founded
2002
GenScript is Hiring for 55 Jobs on Simplify!
Find jobs on Simplify and start your career today